Showing posts with label Treatment. Show all posts
Showing posts with label Treatment. Show all posts

Friday, September 27, 2013

0 The Effectiveness of Modern Antihistamines for Treatment of Allergic Rhinitis

Abstract




 ORIGINAL ARTICLE
The Effectiveness of Modern Antihistamines for Treatment of Allergic Rhinitis – An IPD Meta-Analysis of 140,853 Patients
doi:10.2332/allergolint.12-OA-0486



Ralph Mösges, Volker König and Juliane Köberlein [About this authors]
ABSTRACT
Background: Allergic rhinitis represents a worldwide health problem. The prevalence is increasing. The aim of this study was to analyse the correlation between the severity of allergic rhinitis and an adequate treatment dose of modern oral antihistamines.
Methods: From a comprehensive databank containing data from ten different open-label prospective observational studies including raw data of 140,853 patients with allergic rhinitis, symptomatology variables were analysed and scored to study the effects of treatment with four antihistamines (Desloratadine, Ebastine, Fexofenadine, Levocetirizine) alone or in combination with intranasal corticosteroids. The patient data were collected in 23,606 study centres from Germany, mostly medical specialist and some primary care physicians in private practice. The analyses were performed via individual patient data meta-analysis techniques.
Results: Finally 92,900 patient data from nine of ten studies could be analysed. One study with data of 47,953 patients was excluded due to incomplete treatment documentation. Both monotherapy analysis subgroups (Total Symptom Score and Total Nasal Symptom Score) were significantly better than those of their combinations with intranasal steroids. Monotherapy with levocetirizine was determined to be significantly more effective in lowering the Total Symptom Score (p < 0.001) and the Total Nasal Symptom Score (p < 0.05) than the other antihistamines. In the next stage, a greater positive effect of levocetirizine was demonstrated in relation to the severity of the clinical symptoms of allergic rhinitis (Total Nasal Symptom Score in cases with severe symptomatology [effect size = -0.09]).
Conclusions: Levocetirizine asserted itself as the only antihistamine compared with the others as significant in this analysis. The study authors recommend monotherapy with the new-generation antihistamine levocetirizine, especially in severe cases of allergic rhinitis.

KEY WORDS:
allergic rhinitis, Desloratadine, Ebastine, Fexofenadine, Levocetirizine, treatment
ABBREVIATIONS:
TNSS, Total Nasal Symptom Score; TOSS,Total Ocular Symptom Score; TSS, Total Symptom Score; IPD, Individual Patient Data.

Received: 30 July 2012.
Accepted: 28 November 2012.
Allergology International : In Press








Sunday, September 22, 2013

New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News




This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2005. The length of the article is 835 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.


Citation Details
Title: New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION)
Author:



List Price: $ 5.95


Price: $ 5.95


Information on Asthma from Gooasthma.info Choices including causes, symptoms, diagnosis, risks and treatment and with links to other useful resources.
New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News


Inhaled corticosteroids and fetal growth.: An article from: Internal Medicine News





This digital document is an article from Internal Medicine News, published by Thomson Gale on April 15, 2006. The length of the article is 823 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.


Citation Details
Title: Inhaled corticosteroids and fetal growth.
Author: Gideon Koren
Publication: Internal Med



List Price: $ 5.95


Price: $ 5.95


Information on Asthma from Gooasthma.info Choices including causes, symptoms, diagnosis, risks and treatment and with links to other useful resources.
Inhaled corticosteroids and fetal growth.: An article from: Internal Medicine News


More Corticosteroids Asthma Products



Orignal From: New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News

0 The Influence of the Time and Temperature of Heat Treatment on the Allergenicity of Egg White Proteins


















Original Article  Open Access


















 |  | Full Text    |   

















Allergy Asthma Immunol Res. 2013 Mar;5(2):96-101. English.
Published online 2012 November 02.  http://dx.doi.org/10.4168/aair.2013.5.2.96 
Copyright © 2013 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease










































The Influence of the Time and Temperature of Heat Treatment on the Allergenicity of Egg White Proteins

Meeyong Shin,1 Youngshin Han,2 and Kangmo Ahn3

1Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

2Environmental Health Center for Atopic Dermatitis, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

 Correspondence to: Kangmo Ahn, MD, PhD, Department of Pediatrics, Sungkyunkwan University Samsung Medical Center, 80 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3530; Fax: +82-2-3410-3669; Email:kmaped@skku.edu 

Received July 27, 2012; Revised August 24, 2012; Accepted September 17, 2012.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose
The present study was performed to determine the factor, either duration or the temperature of heat treatment, exerting maximal and significant influence on the composition and allergenicity of egg white (EW) proteins.


Methods
Raw EW and 4 kinds of heated EW (fried EW, boiled EW for 10 minutes, boiled EW for 30 minutes, and baked EW for 20 minutes at 170℃) were prepared, and subsequently protein extraction was carried out. The proteins were separated by SDS-PAGE, and then immunoglobulin E (IgE) immunoblots were performed with the sera of 7 egg-allergic patients. Furthermore, the antigenic activities of ovalbumin (OVA), ovomucoid (OM), and ovotransferrin (OT) in different EW samples were measured by inhibition enzyme-linked Immuno-sorbent assay (ELISA).


Results
In SDS-PAGE analysis, the intensity of the protein band at 45 kD (corresponding to OVA) decreased significantly in boiled EW (30 minutes) and baked EW, but no change was observed in the case of boiled EW for 10 minutes. In IgE immunoblots, the IgE response to 34-50 kD (OM and OVA) in boiled EW for 30 minutes decreased significantly, when compared with raw EW and other heated EWs. In inhibition ELISA, a significant decrease in the OVA antigenic activity was observed in boiled EW for 30 minutes amongst other heated EW samples. However, OM antigenic activity in all kinds of heated EW including boiled EW for 30 minutes did not reduce after heat treatment. The OT antigenic activity nearly disappeared in heated EWs except in the case of boiled EW for 10 minutes.


Conclusions
Amongst 4 kinds of heated EWs, the boiled EW for 30 minutes showed the most significant changes both in composition and reduction in allergenicity. Our results revealed that the duration of heat treatment had more influence on the composition and allergenicity of EW proteins than the temperature.









Thursday, September 19, 2013

0 Acute treatment of anaphylaxis in children


Logo of canfamphys









Can Fam Physician. 2013 July; 59(7): 740-741.





PMCID: PMC3710037





Acute treatment of anaphylaxis in children



Traitement d’urgence de l’anaphylaxie chez les enfants



Ran D. Goldman, MD FRCPC







Abstract



Question A 3-year-old was rushed to my office after eating a friend’s chocolate bar that contained nuts. He immediately developed urticaria on his face and swelling of his lips, and he had a persistent cough. What is the best treatment for a child with anaphylaxis? Should this family receive a prescription for an epinephrine autoinjector device?

Answer Intramuscular epinephrine injection is a safe and effective treatment of anaphylaxis in children. Children with systemic allergic reactions should carry epinephrine autoinjectors at all times, and should certainly have one with them at school. In order for epinephrine autoinjectors to be effective, children and their families need to be educated on how to properly use the devices, as well as keep in mind the product’s expiration date.





Formats:









Tuesday, September 17, 2013

0 A review on guidelines for management and treatment of common variable immunodeficiency



Summary


June 2013, Vol. 9, No. 6, Pages 561-575 , DOI 10.1586/eci.13.30

(doi:10.1586/eci.13.30)





Review

  

A review on guidelines for management and treatment of common variable immunodeficiency



Hassan Abolhassani1, Babak Torabi Sagvand1, Tahaamin Shokuhfar1, Babak Mirminachi1, Nima Rezaei1,2 and Asghar Aghamohammadi*1


* Author for correspondence



Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults. As symptoms of CVID are usually heterogeneous and unspecific, diagnosis and follow-up of CVID can be challenging. In light of this, a broad review of advances in management and treatment of CVID is performed here in order to reach a distinct protocol. However, it should be noted that owing to the nature of the disease, it can only be treated symptomatically but not cured. There is little evidence to guide appropriate or universal guidelines to improve the current status of management of the disease. The most satisfactory treatments of CVID could be achieved by the use of immunoglobulin replacement, antibiotics, immunosuppressants and hematopoietic stem cell transplantation. This review is written based on the importance of clinical surveillance of asymptomatic CVID cases and early recognition of different clinical complications. Moreover, for each complication, appropriate interventions for improving outcomes are mentioned.







Full TextPDF (4044 KB)PDF Plus (4166 KB)



Monday, September 16, 2013

0 Acute rhinosinusitis: New guidelines for diagnosis and treatment


Journal of the American Academy of Physician Assistants:


doi: 10.1097/01.JAA.0000431519.28443.5e

Special Topics in Otolaryngology






Acute rhinosinusitis: New guidelines for diagnosis and treatment



Teeters, Jennifer ATC; Boles, Michelle; Ethier, Julie; Jenkins, Ambria; Curtis, L. Gail PA-C, MPAS




Free Access





Article Outline


Collapse Box

Author Information





Jennifer Teeters, Michelle Boles, Julie Ethier, and Ambria Jenkins are graduates of the PA program at Wake Forest School of Medicine, Winston-Salem, North Carolina. L. Gail Curtis is an associate professor and vice chair of the department of physician assistant studies at Wake Forest School of Medicine. The authors have indicated no relationships to disclose relating to the content of this article.

Roy A. Borchardt, PA-C, PhD, department editor.




Collapse Box

Abstract





ABSTRACT: New treatment guidelines for acute rhinosinusitis outline when antibiotic therapy is appropriate, as well as describe evidence-based treatment to relieve symptoms, prevent complications, and prevent chronic disease.


Article Tools





0 Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity




Thorax doi:10.1136/thoraxjnl-2012-202878




  • Chronic obstructive pulmonary disease



  • Original article



Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity


Open Access















  1. Dirkje S Postma1,2


+Author Affiliations




  1. 1Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  2. 2GRIAC (Groningen Research Institute for Asthma and COPD), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  3. 3Division of Computational Biomedicine, Department of medicine, Boston University School of Medicine, Boston, Massachusetts, USA




  4. 4Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  5. 5Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands




  6. 6Department of Respiratory Medicine, F5-259, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands




  7. 7Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA





  1. Correspondence toDr M van den Berge, Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9700 RB, The Netherlands;m.van.den.berge@umcg.nl




  • Received 16 October 2012


  • Revised 4 June 2013


  • Accepted 30 June 2013


  • Published Online First 7 August 2013




Abstract



Background A core feature of chronic obstructive pulmonary disease (COPD) is the accelerated decline in forced expiratory volume in one second (FEV1). The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone±salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown.



Methods Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone±salmeterol and placebo treatment in GLUCOLD.



Results Linear mixed effects modelling revealed that the expression of 138 genes decreased, whereas the expression of 140 genes significantly upregulated after both 6 and 30 months of treatment with fluticasone±salmeterol versus placebo. A more pronounced treatment-induced change in the expression of 50 and 55 of these 278 genes was associated with a lower rate of decline in FEV1 and Saint George Respiratory Questionnaire, respectively. Genes decreasing with treatment were involved in pathways related to cell cycle, oxidative phosphorylation, epithelial cell signalling, p53 signalling and T cell signalling. Genes increasing with treatment were involved in pathways related to focal adhesion, gap junction and extracellular matrix deposition. Finally, the fluticasone-induced gene expression changes were enriched among genes that change in the airway epithelium in smokers with versus without COPD in an independent data set.



Conclusions The present study suggests that gene expression in biological pathways of COPD is dynamic with treatment and reflects disease activity. This study opens the gate to targeted and molecular phenotype-driven therapy of COPD.

This Article



This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/3.0/